Calcium Channel blockers are associated with reduced risk of Parkinson's disease in patients with hypertension: A population-based retrospective cohort study

被引:18
作者
Tseng, Yuan-Fu [1 ]
Lin, Hsiu-Chen [2 ,3 ]
Chao, Jane Chen-Jui [4 ,5 ]
Hsu, Chien-Yeh [6 ]
Lin, Hsiu-Li [1 ]
机构
[1] Sijhih Cathay Gen Hosp, Dept Neurol, New Taipei, Taiwan
[2] Taipei Med Univ, Sch Med, Dept Pediat, Coll Med, Taipei, Taiwan
[3] Taipei Med Univ Hosp, Dept Lab Med, Taipei, Taiwan
[4] Taipei Med Univ, Sch Nutr & Hlth Sci, Coll Nutr, Taipei, Taiwan
[5] Taipei Med Univ Hosp, Nutr Res Ctr, Taipei, Taiwan
[6] Natl Taipei Univ Nursing & Hlth Sci, Dept Informat Management, Taipei, Taiwan
关键词
Calcium channel blocker; Dihydropyridine; Parkinson's disease; Hypertension; National Health Insurance Research Dataset; MITOCHONDRIAL OXIDANT STRESS; NEURONAL VULNERABILITY; DOPAMINERGIC-NEURONS;
D O I
10.1016/j.jns.2021.117412
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: The use of dihydropyridine calcium channel blockers (DCCBs) was proposed to reduce the risk of Parkinson's disease (PD). This study aimed to evaluate the association between DCCB and its dose effect and the risk of PD in patients with newly diagnosed hypertension. Methods: This population-based retrospective cohort study enrolled 107,207 patients with newly diagnosed hypertension, between 2001 and 2013, from Taiwan's National Health Insurance Research Database. Patients who had PD before hypertension or were taking antipsychotics for more than 30 days in the 6 months prior to the end of the observation period were excluded. A Cox proportional hazard model was used to estimate the risk of PD in different groups. The dose-related effects of DCCB on the risk of PD were evaluated according to the cumulative defined daily dose (DDD). Results: We observed 832 (1.2%) PD cases in patients treated with DCCB as compared to 950 (2.4%) PD cases in those not treated with DCCB, during a median follow-up duration of 8.3 years and 6.2 years, respectively. The risk of PD in the DCCB-treated group (hazard ratio [HR] = 0.50) was significantly lower than that in the group without DCCB treatment. DCCB reduced the risk of PD in a dose-dependent manner, with HRs ranging from 0.61 to 0.37 for DDDs of 90-180 to >720. Conclusions: DCCB treatment was associated with a significantly reduced risk of PD in patients with newly diagnosed hypertension. Further clinical trials are needed to confirm the proposed neuroprotective effects of DCCB in PD.
引用
收藏
页数:6
相关论文
共 33 条
[1]   The epidemiology of Parkinson's disease: risk factors and prevention [J].
Ascherio, Alberto ;
Schwarzschild, Michael A. .
LANCET NEUROLOGY, 2016, 15 (12) :1255-1270
[2]   Use of antihypertensives and the risk of Parkinson disease [J].
Becker, Claudia ;
Jick, Susan S. ;
Meier, Christoph R. .
NEUROLOGY, 2008, 70 (16) :1438-1444
[3]   Drug-Induced Parkinsonism: A Review of 17 Years' Experience in a Regional Pharmacovigilance Center in France [J].
Bondon-Guitton, Emmanuelle ;
Perez-Lloret, Santiago ;
Bagheri, Haleh ;
Brefel, Christine ;
Rascol, Olivier ;
Montastruc, Jean-Louis .
MOVEMENT DISORDERS, 2011, 26 (12) :2226-2231
[4]   Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease [J].
Burbulla, Lena F. ;
Song, Pingping ;
Mazzulli, Joseph R. ;
Zampese, Enrico ;
Wong, Yvette C. ;
Jeon, Sohee ;
Santos, David P. ;
Blanz, Judith ;
Obermaier, Carolin D. ;
Strojny, Chelsee ;
Savas, Jeffrey N. ;
Kiskinis, Evangelos ;
Zhuang, Xiaoxi ;
Kruger, Rejko ;
Surmeier, D. James ;
Krainc, Dimitri .
SCIENCE, 2017, 357 (6357) :1255-+
[5]   'Rejuvenation' protects neurons in mouse models of Parkinson's disease [J].
Chan, C. Savio ;
Guzman, Jaime N. ;
Ilijic, Ema ;
Mercer, Jeff N. ;
Rick, Caroline ;
Tkatch, Tatiana ;
Meredith, Gloria E. ;
Surmeier, D. James .
NATURE, 2007, 447 (7148) :1081-U5
[6]   AGING AND PARKINSONS-DISEASE - SUBSTANTIA-NIGRA REGIONAL SELECTIVITY [J].
FEARNLEY, JM ;
LEES, AJ .
BRAIN, 1991, 114 :2283-2301
[7]  
Garcia-Ruiz P J, 1998, Parkinsonism Relat Disord, V4, P211, DOI 10.1016/S1353-8020(98)00032-7
[8]   Calcium entry induces mitochondrial oxidant stress in vagal neurons at risk in Parkinson's disease [J].
Goldberg, Joshua A. ;
Guzman, Jaime N. ;
Estep, Chad M. ;
Ilijic, Ema ;
Kondapalli, Jyothisri ;
Sanchez-Padilla, Javier ;
Surmeier, D. James .
NATURE NEUROSCIENCE, 2012, 15 (10) :1414-1421
[9]   Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1 [J].
Guzman, Jaime N. ;
Sanchez-Padilla, Javier ;
Wokosin, David ;
Kondapalli, Jyothisri ;
Ilijic, Ema ;
Schumacker, Paul T. ;
Surmeier, D. James .
NATURE, 2010, 468 (7324) :696-U119
[10]   Secondary parkinsonism due to drugs, vascular lesions, tumors, trauma, and other insults [J].
Hoellerhage, Matthias .
PARKINSONISM BEYOND PARKINSON'S DISEASE, 2019, 149 :377-418